CD33 and acute myeloid leukemia: Based on the results of the ALFA-0701 study in newly diagnosed patients [25], the AML-19 study in patients with newly diagnosed AML unsuitable for intensive chemotherapy [35], and the MyloFrance-1 study in relapsed/refractory AML [36], GO was reapproved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed CD33-positive AML in adults and treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older.